CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 454 enrolled
Drug / intervention
JE-CV Vaccine +1 morebiological
Likely dose
JE-CV Vaccine 0.5 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01190228
NCT01190228Phase 3Completed

Assessment of the Memory Immune Response, Safety of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Previously Immunized With a Single Dose of JE-CV and Long-Term Follow-Up

Sanofi Pasteur, a Sanofi Company·interventional·Posted Aug 27, 2010·Updated Mar 28, 2022

In Brief

A Phase 3 clinical trial evaluating JE-CV Vaccine and Varicella Vaccine for Japanese Encephalitis and Varicella. Completed, enrolled 454 participants across 1 site.

Detailed Summary

The aim of the study is to investigate the memory immune response and the yearly persistence of the immunity against Japanese Encephalitis (JE) after vaccination with Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in participants previously vaccinated with JE-CV vaccine. Objectives: * To describe JE immune status before and after JE-CV vaccination in subjects previously vaccinated with JE-CV vaccine * To describe the immune status before and after JE-CV vaccination in JE-naïve control subjects. * To describe the safety (in terms of solicited and unsolicited adverse events) of a single dose of JE-CV vaccine up to 6 months after the last vaccination. * To describe all related serious adverse events (SAEs) and related deaths from 6 months to 5 years after vaccination in JE-CV-primed subjects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesPhilippines
Collaborators--

Timeline

Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedAug 27, 2010
Enrollment StartAug 25, 2010
Primary CompletionOct 29, 2010
Study CompletionOct 12, 2015
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 15.8 years ago

Interventions

JE-CV Vaccinebiological

0.5 mL (single dose), Subcutaneous

Varicella Vaccinebiological

0.5 mL (single dose), Subcutaneous